| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Bohemine, structurally similar to Olomoucine and Roscovitine, is a novel, potent, selective, and cell-permeable cyclin-dependent kinase (CDK) with IC50s of 4.6, 83, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine exhibits a 52 μM IC50 for ERK2 inhibition, while its impact on CDK1, CDK4, and CDK6 is lessened. The anti-cancer effects of bohemine are wide-ranging.
| Targets |
CDK2/cyclinE (IC50 = 4.6 μM); cdk2/cyclin A (IC50 = 83 μM); CDK9/cyclinT1 (IC50 = 2.7 μM); ERK2 (IC50 = 52 μM)
|
|---|---|
| ln Vitro |
Bohemine treatment inhibits cell growth. When bohemine is added at concentrations between 1 and 10 µM, growth and the production of monoclonal antibodies are temporarily stopped. Following the brief suppression of cell functions, there is a notable, transient increase in both the rate of specific growth and production[1].
The G1/S and G2/M boundaries of hybridoma cells are retarded, based on the concentration of bohemine (0-30 µM)[1]. T-cell lymphoblastic line Five proteins are shown to be downregulated when bohemine is used to treat CEM: α-enolase, triosephosphate isomerase, initiation factor 5A, and the α- and β-subunits of Rho GDP-dissociation inhibitor 1. These proteins are important for the processes of glycolysis, proteosynthesis, and cytoskeleton rearrangement[1]. With an IC50 of 27 µM, bohemine inhibits the growth of human tumor cell lines[2]. |
| ln Vivo |
Bohemine (50 mg/kg; intravenous injection; BALB/c mice) treatment reveals a T1/2 of 1.39 hours, an observed clearance of 0.23 L/h, and a Cmax of 72,308 nM[2].
|
| Animal Protocol |
BALB/c mice bearing the colon 26 murine tumor[2]
50 mg/kg Intravenous injection (Pharmacokinetic Analysis) |
| References |
|
| Molecular Formula |
C18H24N6O
|
|---|---|
| Molecular Weight |
340.42276
|
| Exact Mass |
340.20
|
| Elemental Analysis |
C, 63.51; H, 7.11; N, 24.69; O, 4.70
|
| CAS # |
189232-42-6
|
| Related CAS # |
189232-42-6
|
| Appearance |
Solid powder
|
| SMILES |
CC(C)N1C=NC2=C(N=C(N=C21)NCCCO)NCC3=CC=CC=C3
|
| InChi Key |
OPQGFIAVPSXOBO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H24N6O/c1-13(2)24-12-21-15-16(20-11-14-7-4-3-5-8-14)22-18(23-17(15)24)19-9-6-10-25/h3-5,7-8,12-13,25H,6,9-11H2,1-2H3,(H2,19,20,22,23)
|
| Chemical Name |
3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]propan-1-ol
|
| Synonyms |
Bohemine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 68~100 mg/mL (199.8~293.8 mM)
Ethanol: ~68 mg/mL (199.8 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9375 mL | 14.6877 mL | 29.3755 mL | |
| 5 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL | |
| 10 mM | 0.2938 mL | 1.4688 mL | 2.9375 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
